Company Overview

Lantern Pharma Inc. is a U.S.-based clinical-stage biotechnology company focused on developing precision oncology therapies through the integration of artificial intelligence, machine learning, and genomic data analytics. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on cancer therapeutics targeting genetically defined patient populations. Lantern Pharma’s core strategy centers on identifying biomarker-driven cancer indications and optimizing drug development through its proprietary AI platform, RADR® (Response Algorithm for Drug Positioning & Rescue).

The company’s primary revenue-generating potential is tied to the advancement and commercialization of its oncology drug candidates, although it has historically generated limited operating revenue as a development-stage enterprise. Lantern Pharma’s pipeline includes compounds such as LP-300, LP-184, and LP-284, which are being evaluated for multiple cancer indications including lung cancer, glioblastoma, and hematologic malignancies. Originally founded in 2013 and later becoming publicly traded on the NASDAQ under the ticker LTRN, the company evolved from a drug repurposing and analytics-focused model into a precision oncology platform company emphasizing AI-enabled drug development efficiency and biomarker-guided therapies.

Business Operations

Lantern Pharma primarily operates through a single biotechnology and oncology therapeutics business segment focused on drug development and computational oncology. Its operations combine traditional pharmaceutical research and development with proprietary data science capabilities. The company’s central technology asset is the RADR® platform, which integrates genomic, transcriptomic, drug-response, and clinical datasets to identify patient populations most likely to respond to targeted therapies. The platform is designed to reduce development timelines and improve probability of clinical success by identifying biomarker-linked therapeutic opportunities.

The company conducts operations primarily in the United States but collaborates with research institutions, clinical investigators, and contract research organizations internationally. Lantern Pharma controls several internally developed drug assets and has expanded its operational footprint through subsidiaries and partnerships. Its subsidiary Starlight Therapeutics Inc. focuses on central nervous system and brain cancer therapies, particularly glioblastoma and pediatric cancers. Lantern Pharma also collaborates with academic institutions and cancer research centers for clinical trials, translational research, and biomarker validation initiatives.

Strategic Position & Investments

Lantern Pharma’s strategic direction centers on advancing precision oncology therapies while leveraging artificial intelligence to improve drug development economics and clinical targeting. The company prioritizes therapies with biomarker-defined patient populations, orphan indications, and opportunities for accelerated regulatory pathways. Its development model emphasizes rescuing or repositioning underutilized oncology compounds using AI-driven analyses, which differentiates the company from traditional discovery-focused biotechnology firms.

Key strategic investments have included the continued expansion of the RADR® platform, clinical advancement of LP-184 and LP-300, and the development of brain cancer programs through Starlight Therapeutics Inc. The company has also invested in expanding its data infrastructure and computational biology capabilities. Lantern Pharma has highlighted emerging areas such as synthetic lethality, DNA damage response pathways, and AI-assisted oncology drug development as major long-term focus areas. Public disclosures and SEC filings indicate continued emphasis on strategic collaborations, intellectual property expansion, and clinical trial execution rather than large-scale acquisitions.

Geographic Footprint

Lantern Pharma is headquartered in Dallas, Texas, and maintains its primary operational and corporate presence within the United States. Its clinical development activities extend across multiple U.S. research institutions and oncology centers, with some clinical and research collaborations involving international investigators and organizations. The company’s market presence remains primarily North American due to its clinical-stage status and lack of commercialized products.

Although Lantern Pharma does not currently maintain a broad commercial infrastructure across continents, its intellectual property strategy and clinical development programs have international implications in oncology markets. The company’s research collaborations and regulatory ambitions position it for potential future expansion into regions including Europe and Asia-Pacific, particularly in precision oncology and rare cancer indications where biomarker-driven therapies are increasingly prioritized.

Leadership & Governance

Lantern Pharma’s leadership team combines biotechnology, pharmaceutical development, oncology research, and technology expertise. The company was founded by Panna Sharma, who has played a central role in shaping its AI-driven oncology strategy and corporate development efforts. Management has consistently emphasized precision medicine, biomarker-guided trials, and data-centric decision-making as core components of the company’s operating philosophy.

Key executives include:

• Panna Sharma – President and Chief Executive Officer
• David G. Roberts – Chief Financial Officer
• Kishor Bhatia, M.D. – Chief Scientific Officer
• John DiPersio, M.D., Ph.D. – Scientific Advisor and collaborator in oncology initiatives
• Mohit Jitani, M.D. – Chief Medical Officer

The company’s governance structure reflects a biotechnology development-stage model, with oversight focused on clinical execution, regulatory advancement, capital allocation, and intellectual property development. Publicly available disclosures, including SEC filings, indicate that leadership strategy remains centered on advancing targeted oncology assets through data-informed development pathways while maintaining operational flexibility and strategic partnerships.